Infectious Diseases

- Patient is >/= 2 months of age through 16 years of age
- A parent/caregiver must sign an informed consent
- Patient must provide assent, as appropriate based on local institutional review board guidelines

- Patients presenting with the following conditions:
 -- exacerbations of cystic fibrosis (CF)
 -- meningitis
 -- Brain abscess
 -- bacterial endocarditis,
 -- Bone and joint infections
- having any of the following conditions but lacking a personal history may be admitted to the trial:
 -- Arthritis
 -- Juvenile rheumatoid arthritis (JRA)
 -- Rheumatoid arthritis (RA)
 -- Systemic lupus erythematosis (SLE)
 -- History of rheumatic fever
 -- Psoriasis
 -- Inflammatory bowel disease
 -- Osteoarthritis (OA)
- Known underlying rheumatological disease, joint problems known to be associated with arthropathy.
- Patients with any pre-treatment baseline musculoskeletal exam abnormalities
- Known risk of experiencing seizures, a history of any convulsive disorders
- Requiring any concomitant therapeutic course of systemic antibacterial agent
- Participation in any industry-sponsored clinical drug development study within one month prior to this study
- Known significant liver impairment (ALAT/ASAT and/or baseline bilirubin > 3 times upper limit of normal)
- Known significant renal insufficiency (calculated creatinine clearance of < 30 ml/min/1.73 m²)
- Are pregnant or lactating, or are sexually active and using unreliable contraception.